Medication info
Robaga 10 mg (Rosuvastatin Calcium)

Robaga 10 mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Ari Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201906849 · Approved 2019.09.26 · Insurance code 058200250

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults
Adult dosage
1. Primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this medicine should follow a standard cholesterol-lowering diet before and during treatment, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams per day. 2. Elderly patients: Dose adjustment is not necessary. 3. Patients with renal impairment: Dose adjustment is not necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Ingredients

Manufacturer
Ari Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This drug is used as an adjunct to diet in patients with primary hypercholesterolemia and mixed dyslipidemia when dietary measures and exercise alone are insufficient. It is also effective as an adjunct to dietary and other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia. This drug helps lower total cholesterol and LDL-cholesterol levels to target levels in patients with hypercholesterolemia, thereby delaying the progression of atherosclerosis. It is also used as an adjunct to diet in patients with primary dysbetalipoproteinemia, particularly helping reduce risks of stroke, myocardial infarction, and arterial revascularization in middle-aged patients at high cardiovascular risk. Therefore, this drug is effective for lipid control and reducing cardiovascular disease risk.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this medicine should follow a standard cholesterol-lowering diet before and during treatment, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams per day. 2. Elderly patients: Dose adjustment is not necessary. 3. Patients with renal impairment: Dose adjustment is not necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Precautions

This drug should not be used in certain patients. For example, patients who are allergic to this drug, those with severely impaired liver function, muscular diseases, and severely deteriorated kidney function should not take this drug. Women who are pregnant or breastfeeding, or fertile women not using adequate contraception should also avoid this drug. This drug may affect muscles causing symptoms such as myalgia or muscle damage; thus, patients with a history of muscular diseases, elderly patients, or those who consume large amounts of alcohol should consult a doctor before taking it. During treatment, if symptoms such as myalgia, muscle weakness, or fatigue occur, the patient should inform the doctor immediately, and blood tests may be necessary to check for muscle damage. Liver function tests should also be conducted regularly, and if liver enzyme levels become abnormally high, the use of this drug should be discontinued. Extra caution is needed for those with a history of liver diseases or issues with liver function. This drug may interact with other medications, increasing the risk of side effects depending on co-administered drugs. Specifically, the risk of muscle damage may increase when used with certain antiviral agents, immunosuppressants, antifungals, some antibiotics, and fibrate class medications; therefore, it is essential to inform healthcare providers of any medications being taken. Pregnant or breastfeeding women should not take this drug, and women planning to become pregnant should definitely consult before use, as it could harm the fetus and affect the infant through breast milk. In case of overdose, there is no specific antidote, so one should visit a medical institution immediately for appropriate treatment and monitoring. Caution is advised while driving or operating machinery, as dizziness may occur. While taking this drug, regular blood tests and liver function tests are important to detect and manage adverse reactions early.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, hives, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, erythema multiforme-like drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paraesthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly closed container to protect it from air and moisture, and it is safe to store at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain its effectiveness and prevent degradation.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.